Surrozen (NASDAQ:SRZN) Receives Buy Rating from HC Wainwright

Surrozen (NASDAQ:SRZN)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $32.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 187.77% from the stock’s current price.

Separately, Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Friday, January 3rd.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $11.12 on Wednesday. Surrozen has a one year low of $6.00 and a one year high of $18.17. The business’s 50-day moving average price is $11.33 and its two-hundred day moving average price is $11.02.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Monday, March 31st. The company reported ($9.10) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($6.56). The company had revenue of $0.66 million during the quarter. On average, sell-side analysts predict that Surrozen will post -8.49 EPS for the current year.

Insider Activity

In other news, major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average cost of $11.60 per share, with a total value of $11,999,991.20. Following the acquisition, the insider now owns 795,411 shares in the company, valued at approximately $9,226,767.60. This represents a -432.71 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 43.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SRZN. Geode Capital Management LLC increased its stake in shares of Surrozen by 26.1% in the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock worth $321,000 after purchasing an additional 4,630 shares during the period. Trustees of Columbia University in the City of New York acquired a new stake in Surrozen in the 4th quarter valued at approximately $688,000. Adage Capital Partners GP L.L.C. bought a new position in Surrozen in the 4th quarter worth approximately $928,000. Regents of The University of California acquired a new position in shares of Surrozen during the fourth quarter worth approximately $1,912,000. Finally, Stonepine Capital Management LLC boosted its position in shares of Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after acquiring an additional 27,200 shares during the period. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.